Visualization 3.the laser spot near the bottom of the cuvette.mp4

when the laser spot was near the bottom of the cuvette, the gold particles were deposited on the botto

Visualization 4.nanoparticles cannot be captured.mp4

nanoplastics are hardly captured in the nanoplastic solution with the laser o

Visualization 1.Photothermal traps capture nanoparticles .(2.5x speed) .mp4

the directional movement of gold nanoparticles could be observed when the very dilute gold nanosol (to prevent the formation of gold microparticles) was irradiated by lase

Visualization 2.the laser spot away from the bottom of the cuvette.mp4

when the laser spot was far from the bottom of the cuvette, only circulation of the gold particles was observe

Visualization 5.nanoparticles can be captured.mp4

after the gold nanoparticles are mixed into the nanoplastic solution, the directional manipulation of nanoplastics is realize

<i>Tg-I</i> expresses high level of <i>def</i> specifically in the liver.

<p>(<b>A</b>) WISH analysis of <i>def</i> expression in <i>Tg-I</i> and wildtype (WT) embryos at 4.5 dpf using the full length <i>def</i> cDNA as a probe. lv: liver, in: intestine. (<b>B</b>) Western blot of Def in <i>Tg-I</i> and wildtype (WT) embryos at 4.5 dpf. GAPDH: loading control. (<b>C</b>) Immunostaining of Def (green) and the nucleolar marker Fibrillarin (Fib) (red) in the liver of <i>Tg-I</i> fish at 4.5. DAPI was used to stain the nucleoli.</p

Quality assessment of the included trials.

<p>Quality assessment of the included trials.</p

The efficacy of chimeric antigen receptor (CAR) immunotherapy in animal models for solid tumors: A systematic review and meta-analysis

<div><p>Background</p><p>Most recently, an emerging theme in the field of tumor immunology predominates: chimeric antigen receptor (CAR) therapy in treating solid tumors. The number of related preclinical trials was surging. However, an evaluation of the effects of preclinical studies remained absent. Hence, a meta-analysis was conducted on the efficacy of CAR in animal models for solid tumors.</p><p>Methods</p><p>The authors searched PubMed/Medline, Embase, and Google scholar up to April 2017. HR for survival was extracted based on the survival curve. The authors used fixed effect models to combine the results of all the trials. Heterogeneity was assessed by I-square statistic. Quality assessment was conducted following the Stroke Therapy Academic Industry Roundtable standard. Publication bias was assessed using Egger's test.</p><p>Results</p><p>Eleven trials were included, including 54 experiments with a total of 362 animals involved. CAR immunotherapy significantly improved the survival of animals (HR: 0.25, 95% CI: 0.13–0.37, P < 0.001). The quality assessment revealed that no study reported whether allocation concealment and blinded outcome assessment were conducted, and only five studies implemented randomization.</p><p>Conclusions</p><p>This meta-analysis indicated that CAR therapy may be a potential clinical strategy in treating solid tumors.</p></div

Subgroup analysis by cancer type, target, generation, animal model, and publication year.

<p>Subgroup analysis by cancer type, target, generation, animal model, and publication year.</p

Characterization of a Novel Butachlor Biodegradation Pathway and Cloning of the Debutoxylase (Dbo) Gene Responsible for Debutoxylation of Butachlor in Bacillus sp. hys‑1

Bacillus sp. strain hys-1, which was isolated from active sludge, could degrade >90% butachlor at a concentration of 100 mg/L within 7 days. The present work revealed that strain hys-1 could mineralize butachlor via the following pathway: butachlor was initially metabolized to 2-chloro-<i>N</i>-(2,6-diethylphenyl)-<i>N</i>-methylacetamide by debutoxylation and then transformed to form 2-chloro-<i>N</i>-(2,6-diethylphenyl)­acetamide by N-demethylation. Subsequently, it was converted to 2,6-diethylaniline and further mineralized into CO₂ and H₂O. In addition, the catalytic efficiency of crude cell extracts descended as follows: alachlor > acetochlor > butachlor. Furthermore, a novel 744 bp gene responsible for transforming butachlor into 2-chloro-<i>N</i>-(2,6-diethylphenyl)-<i>N</i>-methylacetamide was cloned from strain hys-1 and the encoding debutoxylase was designated Dbo. Then Dbo was expressed in Escherichia coli BL21 (DE3) and purified using Ni–nitrilotriacetic acid affinity chromatography. Dbo displayed the highest activity against butachlor at pH 6.5 and 30 °C. Metal ions played an important role in Dbo activity. To the best of the authors’ knowledge, this is the first report that strain hys-1 can mineralize butachlor by a novel metabolic mechanism and the first identification of a gene encoding butachlor debutoxylase